How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals

Hdl Handle:
http://hdl.handle.net/10144/37354
Title:
How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals
Authors:
van Roey, J; von Schoen-Angerer, T; Ford, N; Calmy, A
Journal:
Drug Discovery Today
Abstract:
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.
Affiliation:
Médecins Sans Frontières, Campaign for Access to Essential Medecins, Geneva, Switzerland; Médecins Sans Frontières, Khayelitsha, South Africa; Geneva Teaching Hospital, Geneva, Switzerland
Issue Date:
Jul-2008
URI:
http://hdl.handle.net/10144/37354
DOI:
10.1016/j.drudis.2008.04.009
PubMed ID:
18598916
Additional Links:
http://www.sciencedirect.com/science/journal/13596446
Submitted date:
2008-08-28
Type:
Article
Language:
en
ISSN:
1359-6446
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorvan Roey, J-
dc.contributor.authorvon Schoen-Angerer, T-
dc.contributor.authorFord, N-
dc.contributor.authorCalmy, A-
dc.date.accessioned2008-09-05T10:22:17Z-
dc.date.available2008-09-05T10:22:17Z-
dc.date.issued2008-07-
dc.date.submitted2008-08-28-
dc.identifier.citationDrug Discov Today 2008;13(13-14):601-5en
dc.identifier.issn1359-6446-
dc.identifier.pmid18598916-
dc.identifier.doi10.1016/j.drudis.2008.04.009-
dc.identifier.urihttp://hdl.handle.net/10144/37354-
dc.description.abstractClinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.en
dc.language.isoenen
dc.relation.urlhttp://www.sciencedirect.com/science/journal/13596446en
dc.rightsArchived on this site by kind permission and copyright 2008 by Elsevieren
dc.subject.meshClinical Trialsen
dc.subject.meshDeveloping Countriesen
dc.subject.meshAntiretroviral Agentsen
dc.subject.meshHighly Active Antiretroviral Therapyen
dc.titleHow developing world concerns need to be part of drug development plans: A case study of four emerging antiretroviralsen
dc.typeArticleen
dc.contributor.departmentMédecins Sans Frontières, Campaign for Access to Essential Medecins, Geneva, Switzerland; Médecins Sans Frontières, Khayelitsha, South Africa; Geneva Teaching Hospital, Geneva, Switzerlanden
dc.identifier.journalDrug Discovery Todayen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.